News Briefs

The FDA approved an additional indication for Jardiance (empagliflozin), allowing the drug to be used to “reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF),” according to a press release from Boehringer Ingelheim and Eli Lilly and Co. According to an Aug. 18 press release, the drug was already approved to “lower blood sugar along with diet and exercise in adults with type 2 diabetes, reduce the risk of cardiovascular death in adults with type 2 diabetes who also have known cardiovascular disease, [and] reduce the risk of cardiovascular death and hospitalization for heart failure…in adults with heart failure.”

© 2022 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

pills
September 22

Report Shows Limited Access to Opioid Use Disorder Treatments for Medicare Beneficiaries

READ MORE
cms-website
September 22

Drug Price Negotiation Will Require New CMS Regulations, Staffing

READ MORE
money-stethoscope
September 22

Study: Pharma Companies Often Profit From Donations to Patient Assistance Charities

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today